

## IMAGION BIOSYSTEMS LIMITED

ASX: IBX

8 April 2026

### IBX Update Regarding Short Term Funding Facilities

Imagion Biosystems (ASX: IBX) (**Company** or **Imagion**), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to inform shareholders it has secured short term funding from an investment fund managed by US-based C/M Capital Partners, LP with C/M Capital Master Fund, LP (**CMF**) to provide the Company an additional funding facility of \$300,000 in accordance with the Mercer Street Global Opportunity Fund, LLC (**Mercer Street**) convertible securities agreement (**Agreement**) dated 7 March 2023 (as varied from time to time) following the partial novation of this Agreement to CMF, an affiliated fund of Mercer Street.

Additionally, Imagion and Mercer Street have agreed to amend the terms of the Agreement as follows:

- The maturity date of notes that were due for repayment before the date of this announcement are now extended to 31 December 2026.
- Any new notes issued will have a maturity date of 18 months from the date of issue and a floor price of \$0.025.

*“Having the continued support and cooperation from Mercer Street, and now C/M Capital Partners, as we await the review from the FDA of our Investigational New Drug application is most gratifying” said Executive Chairman Bob Proulx. “We have a shared vision of the value our technology can bring and we greatly appreciate their commitment to Imagion and its shareholders.”*

#### About the Convertible Securities Agreement

As announced on 7 March 2023, the Company entered into a convertible securities agreement with Mercer Street Global Opportunity Fund, LLC (**Mercer**), a US-based investment fund managed by Mercer Street Capital Partners, LLC, as set out in recent Company financial reports.

#### Authorisation & Additional Information

This announcement was authorised by the Board of Imagion Biosystems Limited.

— ENDS —

**Imagion Biosystems Limited**

ASX: [IBX](#) ACN 616 305 027

Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000

[imaginationbiosystems.com](http://imaginationbiosystems.com) | [investor@imaginationbio.com](mailto:investor@imaginationbio.com)



### Join Imagion Biosystems' Investor Hub

Stay up to date on news and announcements or interact with our team through questions and comments via *Investor Hub*. Register at [investor.imagionbiosystems.com](http://investor.imagionbiosystems.com).

### About Imagion Biosystems

Imagion Biosystems (ASX: IBX) is a clinical-stage, medical imaging company dedicated to transforming how cancer is diagnosed and treated. The company produced and is developing clinical applications for MagSense<sup>®</sup>, a first-of-its-class MRI imaging agent that enables clinicians to detect cancer earlier and with greater precision. Advancing molecular MRI, the company is using non-radioactive, bio-safe magnetic nanoparticles to improve diagnostic certainty for a broad range of applications, including HER2+ breast cancer, prostate cancers, and ovarian cancers. For more information, visit [imagionbiosystems.com](http://imagionbiosystems.com).

### Executive Chairman Contact Details

Bob Proulx  
[investor@imagionbio.com](mailto:investor@imagionbio.com)  
AU: +61 3 9692 7222

### Media Enquiries & Investor Relations:

Erich Boileau, Boileau & Co.  
[imagionbio@boileau.co](mailto:imagionbio@boileau.co)  
US : +1 (616) 786-4461

### Imagion Biosystems Limited

ASX: **IBX** ACN 616 305 027  
Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000  
[imagionbiosystems.com](http://imagionbiosystems.com) | [investor@imagionbio.com](mailto:investor@imagionbio.com)

